Tagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR) inhibitor developed by AstraZeneca. Tagrisso has shown clinical activity against the EGFR T790M mutation, which is estimated to be responsible for over half of all cases of resistance to early-generation EGFR tyrosine kinase inhibitors. As a result, Tagrisso not only inhibits tumor growth and induces cell death in previously treated patients with T790M mutation, but the drug may also be a therapeutic option for first-line EGFR-positive patients to prevent de novo resistance due to the T790M mutation. Tagrisso is also more tolerable than early-generation EGFR inhibitors, due to its ability to spare wild-type EGFR, further enhancing its potential as a first-line therapy.
4 Drug Overview
5 Product Profiles
5 Tagrisso : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
13 Figure 98: Entrectinib for non-small cell lung cancer – SWOT analysis
15 Figure 99: Datamonitor Healthcare’s drug assessment summary for entrectinib in non-small cell lung cancer
LIST OF TABLES 6 Table 1: Tagrisso drug profile
7 Table 2: Tagrisso pivotal trial data in non-small cell lung cancer
10 Table 3: Tagrisso ongoing late-phase clinical trials in non-small cell lung cancer
16 Table 4: Tagrisso sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
18 Table 5: Tagrisso patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.